This thread is dedicated to shareholders of http://www.flex-pharma.com/index.php Enjoy!
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, choses his own topics, and his words and opinions are his own. You can see his past columns and most recent comments on his Stock Gumshoe page.] We first presented Gilead ($GILD) as a long idea […]
#Alzheimer’s_disease , #Obesity , #Zika – The #Numbers , #$s , #Mystery , #KASH ; #Past #present & #future
This percolated up to the “most asked about” teaser pitch over the weekend, and it’s easy to see why — everyone loves royalties (or as the newsletters like to call it, “getting money for free without doing any hard work”), and Sid Riggs is saying that “you can get super rich in a matter of […]
The way things appear to be shaping up, at least to me, is that if a Liver or Lung medical breakthrough DOESN’T REVERSE FIBROSIS, then it won’t have any commercial profits/success Anything less than REVERSING fibrosis, will be a HAS BEEN.
[ed. note: Michael Jorrin is a longtime medical writer (not a doctor), I’ve dubbed him “Doc Gumshoe” for his coverage of medical and health topics for Stock Gumshoe. This piece, like most of Michael’s work, is not specifically investment-related — but for those who think about speculating in the next Zika cure or similar “hot […]
This article was originally published on December 17, it has not been edited or revised. The ad from Jimmy Mengel’s The Crow’s Nest is apparently circulating heavily again, because questions are percolating through to me about these “secret marijuana stocks” again… so we’re moving it to the top of the list today for your edutainment. […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, he chooses his own topics, and his words and opinions are his own. You can see his biography, previous columns and most recent comments on his Stock Gumshoe page.] “We ran the race, the race […]
Bonner & Partners, which is yet another spinoff of Bill Bonner’s Agora publishing empire, has beefed up its newsletter offering a bit by launching a new newsletter that’s seems like it’s in the same vein as Agora’s Breakthrough Technology Alert — an expensive letter focused on new technologies and, more specifically, on the early stage […]
[ed. note: Michael Jorrin, who I like to call Doc Gumshoe, is a longtime medical writer (not a doctor) who writes about non-financial health and medical issues for us a couple times a month. Like all of our authors, he chooses his own topics and his words and opinions are his alone. Enjoy!] While working […]
This ad first showed up in our inboxes under the “end surgery forever” headline in late January, and the following article first appeaered on January 26. We have not gone through and updated the article, though the basic pitch is just about the same in the new version of the ad today as it was […]
This pitch comes our way from Shah Gilani for his Capital Wave Forecast ($1,850 “on sale”), whose spiel hints at a stock that can “end the 8 deadliest diseases known to mankind” with a “painless, 5-minute treatment” that is “set to roll out in 246,000 doctors’ offices — and unleash $30 billion in new wealth.” […]
I’ll just start off by telling you that yes, this stock might be one of the most familiar biotech ideas we’ve ever covered here at Stock Gumshoe — not necessarily because I like it or our other writers like it, or even because it’s been a good investment, but because it’s been so aggressively teased […]
Brett Jensen touts a new class of cardiac drugs and the company making it in Biotech Jems. Any ideas?
Just read a downgrade for trxc from streetsweepers calling the company an operational disaster. And they own stocks. Any thoughts.
Stansberry Venture is a high-end ($5,000/yr) newsletter that focuses on small “breakthrough” type companies, so far mostly in biotech and technology as far as I’ve seen. It’s the heir, roughly speaking, of Stansberry’s old Phase 1 newsletter that used to often pitch biotech, tech and junior mining stocks. It’s helmed by Dave Lashmet, who was […]
Another biotech teaser for you today — these never seem to stop, perhaps partly because small biotech stocks are almost the only ones, other than little junior miners, that have a legitimate chance of seeing their prospects change dramatically overnight or see rapid 100%, 200%, 500% share price gains on a new discovery or shockingly […]
dr. on tv talked about new cancer break thru. with 90% results. it’s in 3rd approval stage by fed. any idea who?
[ed. note: Michael Jorrin, who I like to call Doc Gumshoe, is a longtime medical writer (not a doctor) who writes about non-financial health and medical issues for us a couple times a month — this time, he’s covering one of the many over-hyped health ads for “secret” supplements and treatments that we all see […]